We're increasing our Eli Lilly price target after another beat-and-raise quarter

Per CNBC, Eli Lilly beat earnings and raised guidance once more, driven by strength in its GLP-1 business. The analysts are raising the stock's price target in response, suggesting they see room for further growth.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton